Redeye comments on results from the recent BE study with Generic HyNap-Dasa. BE was not met in the trial, and the share was down some 20% on the announcement. Despite the results, we still see a solid fundamental case in Xspray. However, the incoming study with the new formulation will be crucial for positive development in the share. We adjust our valuation.